Epigenetic drugs and their immune modulating potential in cancers

• Verfasst von: Liang, Yingying [VerfasserIn]
• Verfasst von: Turcan, S̨evin [VerfasserIn]
• Titel: Epigenetic drugs and their immune modulating potential in cancers
• Verf.angabe: Yingying Liang and Sevin Turcan
• E-Jahr: 2022
• Jahr: 9 January 2022
• Umfang: 18 S.
• Fussnoten: Gesehen am 23.03.2022
• Titel Quelle: Enthalten in: Biomedicines
• Ort Quelle: Basel : MDPI, 2013
• Jahr Quelle: 2022
• Band/Heft Quelle: 10(2022), 2, Artikel-ID 211, Seite 1-18
• ISSN Quelle: 2227-9059
• DOI: doi:10.3390/biomedicines10020211
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: antiviral response
• Sach-SW: epigenetic drugs
• Sach-SW: epigenetics
• K10plus-PPN: 179641347X

Abstract

Epigenetic drugs are used for the clinical treatment of hematologic malignancies; however, their therapeutic potential in solid tumors is still under investigation. Current evidence suggests that epigenetic drugs may lead to antitumor immunity by increasing antigen presentation and may enhance the therapeutic effect of immune checkpoint inhibitors. Here, we highlight their impact on the tumor epigenome and discuss the recent evidence that epigenetic agents may optimize the immune microenvironment and promote antiviral response.